RECHERCHE :   Cancers du poumon - cancers thoraciques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
ALERT-lung (ETOP 12-17) - A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC
Cancer du poumon non à petites cellules avancé avec réarrangement RET
II
HUG
CA021-002: A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors
Tumeurs solides
I, II
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CACZ885T2301: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Cancer bronchique non à petites cellules complètement réséqué, stade II à IIIA et IIIB
III
HUG
CEGF816X2201C: A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer
Cancer du poumon non à petites cellules avancé et/ou métastatique/inopérable
II
HUG
CHUV-DO-PART-2016: Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment
Cancer du sein, du poumon ou métastases pulmonaires
II
CHUV
IMpower030 - A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non−Small Cell Lung Cancer
Cancer du poumon (NSCLC)
III
CHUV
Merck 3475-495 : A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-Based Combination Therapy for Advanced Non- Small Cell Lung Cancer
Advanced Non- Small Cell Lung Cancer
II
HUG
MERU (Rova-T): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer
Traitement d'entretien pour cancer du poumon à petites cellules au stade étendu
III
HUG
NIVOTHYM- EORTC-1525- Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy
Cancer du thymus
II
CHUV
PEARLS (MK3475-091): A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy
Cancer du poumon non à petites cellules
III
CHUV, HUG
SAKK 19/17 : First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
PD-L1 positive advanced Non Small Cell Lung Cancer
II
HUG